Skip to main content

Table 1 Pre-treatment patient characteristics

From: Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis

Category

 

Number

Percentage

Age (mean ± SD)

 

49.4 ± 10.7 years

Pretreatment size (mean ± SD)

 

5.6 ± 2.8 cm

Chemotherapy regimen

 

Dose dense AC-T

50

48.6

AC-T

18

17.5

FEC-D

29

28.2

ED

1

1.0

TC

4

3.9

Estrogen Receptor Status

 

Positive

66

64.1

Negative

37

35.9

Progesterone receptor status

 

Positive

58

56.3

Negative

45

43.7

HER2 receptor status

 

Positive

32

31.1

Negative

71

68.9

Classification

 

Luminal A

30

29.1

Luminal B (HER2-negative)

17

16.5

Luminal B (HER2-positive)

18

17.5

HER2 positive

13

12.6

Triple-negative

24

23.3

Laterality

 

Left

47

45.6

Right

55

35.4

Bilateral

1

1.0

Menopausal status

 

Pre-menopausal

57

55.3

Post-menopausal

37

35.9

Peri-menopausal

7

6.8

Not available

2

1.9

Histology

 

IDC

97

94.2

ILC

3

2.9

IMC

1

1.0

Mixed ILC/IDC

2

1.9

Lymphovascular invasion

 

Negative

50

48.5

Positive

45

43.7

Not available

8

7.8

T (tumor) stage

 

T1

2

1.9

T2

44

42.7

T3

46

44.7

T4

11

10.7

Clinical N (nodal) stage

 

N0

28

27.2

N1

62

60.2

N2

12

11.7

N3

1

1.0

Stage group

 

IIA

16

15.5

IIB

37

35.9

IIIA

38

6.9

IIIB

11

10.7

IIIC

1

1.0

Pathologic N (nodal) status

 

Negative

10

9.7

Positive

80

77.7

N/A

13

12.6

  1. Abbreviations: A doxorucibin (Adriamycin), C cyclophosphamide, D docetaxel, E epirubicin, F 5-fluorouracil, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, IMC invasive mammary carcinoma, SD standard deviation, T paclitaxel (Taxol)